Masimo Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Masimo stock.
View analyst ratings for Masimo or view top-rated stocks.

Wall Street analysts have given Masimo a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Masimo wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Masimo is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for Masimo.

Masimo will be holding an earnings conference call on Tuesday, July 27th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Masimo Co. (NASDAQ:MASI) issued its quarterly earnings data on Sunday, April, 25th. The medical equipment provider reported $0.90 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.88 by $0.02. The medical equipment provider had revenue of $299.04 million for the quarter, compared to analysts' expectations of $296.22 million. Masimo had a trailing twelve-month return on equity of 14.95% and a net margin of 19.54%. The firm's revenue was up 10.9% compared to the same quarter last year. During the same period last year, the business earned $0.97 earnings per share.
View Masimo's earnings history.

Masimo's stock was trading at $182.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MASI shares have increased by 50.3% and is now trading at $274.54.
View which stocks have been most impacted by COVID-19.

Masimo issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of 3.830-3.830 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.810. The company issued revenue guidance of $1.21 billion-$1.21 billion, compared to the consensus revenue estimate of $1.20 billion.

5 Wall Street analysts have issued 12 month price objectives for Masimo's stock. Their forecasts range from $276.00 to $310.00. On average, they anticipate Masimo's share price to reach $291.50 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price.
View analysts' price targets for Masimo or view top-rated stocks among Wall Street analysts.

136 employees have rated Masimo CEO Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among Masimo's employees.

Some companies that are related to Masimo include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and STERIS (STE).
View all of MASI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), The Trade Desk (TTD), The Walt Disney (DIS) and Twilio (TWLO).

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Masimo's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (1.40%), State of Alaska Department of Revenue (0.06%), Oregon Public Employees Retirement Fund (0.03%), New Mexico Educational Retirement Board (0.02%), Cardinal Capital Management (0.02%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Masimo stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends for Masimo.

MASI stock was sold by a variety of institutional investors in the last quarter, including EFG Asset Management Americas Corp., Cardinal Capital Management, Oregon Public Employees Retirement Fund, and State of Alaska Department of Revenue. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Bilal Muhsin, Craig B Reynolds, Joe E Kiani, Micah W Young, and Thomas Samuel Mcclenahan.
View insider buying and selling activity for Masimo or view top insider-selling stocks.

MASI stock was purchased by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., New Mexico Educational Retirement Board, IFM Investors Pty Ltd, Meridian Wealth Management LLC, and Raymond James Trust N.A..
View insider buying and selling activity for Masimo or or view top insider-buying stocks.

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MASI stock can currently be purchased for approximately $274.54.

Masimo has a market capitalization of $15.10 billion and generates $1.14 billion in revenue each year. The medical equipment provider earns $240.30 million in net income (profit) each year or $3.60 on an earnings per share basis.

Masimo employs 5,300 workers across the globe.

Masimo was founded in 1989.

The official website for Masimo is www.masimo.com.

Masimo is headquartered at 52 DISCOVERY, IRVINE CA, 92618.

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]